posttransplantation lymphoproliferative disorder

posttransplantation lymphoproliferative disorder

A complication of 1-10% of organ transplant recipients, which may be poly- or monoclonal; most affected cells contain EBV, usually latent; post-transplantation Pts at risk for PTLD can be identified by detecting expression–as small mRNA of the EBER-1 gene; most cases that occur in solid organ recipients are of host origin
References in periodicals archive ?
Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder.
The important role of immunostains in evaluation of infection in transplantation is covered in a subsequent section, and posttransplantation lymphoproliferative disorder (PTLD) is discussed briefly.
Reduction of immunosuppression as initiaI therapy for posttransplantation lymphoproliferative disorder.
Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations.
Due to chronic immunosuppression of liver transplant recipients, posttransplantation lymphoproliferative disorder (PTLD), which is often associated with infection from Epstein-Barr virus (EBV), and non-Hodgkin's lymphoma are becoming more common.
Treatment of Epstein-Barr virus-induced posttransplantation lymphoproliferative disorder with foscamet alone in an adult after simultaneous heart and renal transplantation.
CT findings in posttransplantation lymphoproliferative disorder of renal transplants.
It includes infections as well as neoplasms, such as lymphoma, posttransplantation lymphoproliferative disorder, meningioma, and metastases.
Posttransplantation lymphoproliferative disorder complicates approximately 1% of renal transplant patients, with a spectrum of disease ranging from mild diffuse polyclonal lymphadenopathy to malignant monoclonal lymphoma.
The specimens represented numerous histopathologic diagnoses, including non-Hodgkin lymphoma, posttransplantation lymphoproliferative disorder, chronic lymphocytic leukemia/small lymphocytic lymphoma, and benign lymphoid tissue, as well as cell lines obtained from reliable vendors.
Posttransplantation lymphoproliferative disorder (PTLD) occurs in 2% to 10% of adults, with a higher incidence in children and may present as early as 1 month posttransplant.
The unusual presentation of this case also raised the possibility of posttransplantation lymphoproliferative disorder (PTLD).
Full browser ?